Safety and tolerability of adjunctive rosiglitazone treatment for children with uncomplicated malaria

Malaria Journal

Table 2 ECG abnormalities

Patient	Treatment	QTc baseline (ms)	QTc maximum (ms)	ECG findings
ROSI-002	Rosiglitazone	352	407	Increase of QtcF >50 ms on day 4, NCS
ROSI-007	Rosiglitazone	396	427	Increase of QtcF >50 ms on day 2, NCS. Finished on day 4
ROSI-008	Rosiglitazone	356	424	Increase of QtcF >50 ms on day 2, NCS. Continue on day 7, NCS
ROSI-009	Placebo	342	425	Increase of QtcF >50 ms on day 4 with associated bradycardia, NCS Increase of QtcF >50 ms on day 7, NCS and without bradycardia
ROSI-010	Placebo	336	409	Increase of QtcF >50 ms on day 4, NCS. Finished on day 7
ROSI-012	Rosiglitazone	323	404	Increase of QtcF >50 ms on day 2, NCS. Finished on day 4
ROSI-014	Placebo	364	425	Left bundle branch block from screening, NCS Increase of QtcF >50 ms on day 4, NCS. Finished on day 14 Bradycardia on day 4, NCS
ROSI-021	Placebo	361	414	Increase of QtcF >50 ms on day 4, NCS. Finished on day 7
ROSI-022	Placebo	349	402	Increase of QtcF >50 ms on day 4, NCS. Finished on day 7

These abnormalities were not clinically significant (NCS). QT corrected for heart rate using Fridericia’s method

ISSN: 1475-2875